Repros Therapeutics, Inc. (RPRX): Data coming

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Repros Therapeutics, Inc. (RPRX)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	94
Posts	1989
Boards Moderated	0
Alias Born	07/14/2015

Re: None

Thursday, 07/13/2017 6:52:12 AM

Thursday, July 13, 2017 6:52:12 AM

Data coming

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent RPRX News

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/19/2024 12:15:00 PM
Royalty Pharma Declares Second Quarter 2024 Dividend • GlobeNewswire Inc. • 04/17/2024 12:15:00 PM
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:15:00 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 02:05:28 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:33:43 PM
Royalty Pharma Reports Q4 and Full Year 2023 Results • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 12:01:30 PM
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 • GlobeNewswire Inc. • 01/30/2024 09:15:00 PM
Royalty Pharma Announces Dividend Increase • GlobeNewswire Inc. • 01/19/2024 01:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:18:52 PM
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:31:02 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:30:54 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:29:43 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:31:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 06:05:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:30:29 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:02 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/13/2023 09:47:54 PM
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference • GlobeNewswire Inc. • 11/27/2023 09:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:16:52 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 10:13:26 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:35:11 AM
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program • GlobeNewswire Inc. • 11/13/2023 01:10:00 PM
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program • Business Wire • 11/13/2023 01:00:00 PM

More RPRX News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow